Hemispherx Biopharma, Inc.

Manufacturing facility expanded for production of Ampligen

Published in Law and Health Weekly, October 8th, 2005

Hemispherx Biopharma, Inc., (HEB) disclosed by letter to stockholders that it has increased the capacity of its facility in New Brunswick, New Jersey, to manufacture its experimental drug, Ampligen, as well as advancements in the application of Alferon LDO for the potential treatment of Avian influenza.

The letter, which is being submitted as an 8-K with the Securities and Exchange Commission, highlights several key developments currently underway.

Hemispherx is implementing a three-phase strategy in its manufacturing process of Ampligen. The first component in this process highlighted in the stockholder letter is the establishment of production of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2005-10-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry